BioPharma Dive August 12, 2024
Yorvipath, a prodrug formulation of the parathyroid hormone, is now approved to treat adults whose bodies don’t make enough of it.
Dive Brief:
- The Food and Drug Administration on Monday approved a hormonal replacement drug from Ascendis Pharma for a rare endocrine condition known as hypoparathyroidism.
- The drug, which Ascendis will sell as Yorvipath, is a prodrug formulation of the parathyroid hormone, levels of which are insufficiently low in the 70,000 to 90,000 people in the U.S. estimated to have the condition,
- Ascendis is still working on ramping up its manufacturing and plans to make supply of Yorvipath available in the first quarter of next year. Shares in Ascendis rose by as much as 10% Monday morning on the...
Today's Sponsors
Today's Sponsor
